Drug therapies for the primary prevention of cardiovascular events: Trials and errors: 2009 ancel keys memorial lecture

Circulation

Volumn 121, Issue 7, 2010, Pages 940-945

  Psaty, Bruce M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Coronary disease; Diabetes mellitus; Epidemiology; Prevention; Risk factors

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; GLIBENCLAMIDE; METFORMIN; PLACEBO; ROSIGLITAZONE; ROSUVASTATIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 77649086335     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.933705     Document Type: Review

References (50)

1. Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol. October 26 2009. DOI:10.1177/0192623309351719. Available at: http://tpx.sagepub.com. Accessed October 29 2009.
2. Blackburn H. Introduction to Ancel Keys Lecture: Ancel Keys, pioneer. Circulation. 1991;84:1402-1404.
3. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398.
4. Rose G. Ancel Keys Lecture. Circulation. 1991;84:1405-1409.
5. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14: 32-38.
6. Martin MJ, Browner WS, Wentworth D, Hulley SB, Kuller LH. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,622 men. Lancet. 1986;2:933-936.
7. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828
8. Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.
9. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ. 1981;282:1847-1851.
10. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate endpoints, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786-790.
11. Selvin E, Marionoulos S, Berkenbilt G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
12. Kelly T, Bazzano L, Fonseca V, Thethi T, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.
13. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-2559.
14. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Hurang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
16. Goodarzi M, Psaty BM. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA. 2008;300:2051-2053.
17. Floyd J, Barbehenn E, Lurie P, Wolfe S. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2009;18:1238-1243.
18. GlaxoSmithKline. Study No ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. Available at: http://www.gsk-clinicalstudyregister. com/files/pdf/24040.pdf. Accessed February 2 2010.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2472.
20. Levovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosigli-tazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrin Metabol. 2001;86:280-288.
21. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 2002; 287:1680-1689.
22. Misbin RI. Medical office review of Avandia: application number: 021071. Center for Drug Evaluation and Research. Available at: http://oversight.house. gov/images/stories/documents/20070606112934.pdf. Accessed February 2, 2010.
23. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443
24. DREAM (Diabetes Reduction Assessment With Ramipril and Rosigli-tazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368:1096-1105
25. Home PD, Pocock SJ, Beck-Nielson H, Curtis PS, Gamis R, Haenfeld M, Jones NP, Komajda M, McMurray JJV, for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135.
26. Psaty BM, Prentice RL. Variation in event rates in trials of patients with type 2 diabetes. JAMA. 2009;302:1698-1700.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997
28. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
29. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357-1366.
30. Fleming T. Identifying and addressing safety signals in clinical trials. N Engl J Med. 2008;359:1400-1402.
31. Taylor A, Nissen S. Preliminary observations from preliminary trial results: have we finally had enough? Circ Cardiovasc Qual Outcomes. 2008;1:54-57.
32. Brugts J, Yetgin T, Hoeks S, Gotto AM, Shepherd J, Westendorp RGJ, de Craen AJM, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
34. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
35. Pencina M, D'Agostino R Sr, Larson M, Massaro J, Vasan R. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078-3084.
36. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham Score for Risk Prediction in asymptomatic individuals. JAMA. 2004;291:210-215.
37. Detrano R, Guerci A, Carr J, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-1345.
38. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med. 2009;151:483-495.
39. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, Smeeth L, Deanfield JE, Lowe GD, Rumley A, Gowkes FGR, Humphries SE, Hingorani AD. Critical appraisal of CRP measurement for the pre-diction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217-231.
40. Vasan RS. Commentary: C-reactive protein and risk prediction: moving beyond associations to assessing predictive utility and clinical usefulness. Int J Epidemiol. 2009;38:231-234.
41. Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ration in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890.
42. Wald NJ, Morris JK, Rish S. The efficacy of combining risk factors as a screening test. J Med Screen. 2005;12:197-201.
43. Mills E, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.
44. Diamond GA, Kaul S. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. Am J Cardiol. 2007;99:1013-1015.
45. Lauer MS. Discarding logic: 2008 Ancel Keys Memorial Lecture. Circulation. 2009;119:1533-1537.
46. Institute of Medicine Committee on Comparative Effectiveness Research Prioritization. Initial National Priorities for Comparative Effectiveness Research: Report Brief. Washington, DC: Institute of Medicine of the National Academies; 2009.
47. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihyper-tensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
48. Yusuf S, Pais, P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N, for the Indian Polycap Study. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double blind, randomised trial. Lancet. 2009;373:1341-1351.
49. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA. 2004;292:2622-2631.
50. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. JAMA. 2008;299:1813-1817.